Suppr超能文献

髓源性抑制细胞作为细胞免疫疗法在移植和自身免疫性疾病中的应用。

Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.

机构信息

Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States.

Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States; Texas A&M College of Medicine, Bryan, TX, United States.

出版信息

Cell Immunol. 2021 Apr;362:104300. doi: 10.1016/j.cellimm.2021.104300. Epub 2021 Feb 4.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.

摘要

髓系来源的抑制性细胞(MDSCs)是一群异质性的未成熟髓系细胞,其通过多种机制表现出免疫抑制能力。这些细胞在肿瘤免疫领域得到了广泛研究。新出现的证据强调了其在移植和自身免疫中维持免疫耐受的重要作用。由于其强大的免疫抑制活性,基于 MDSC 的细胞治疗越来越受到关注。各种临床前研究表明,MDSC 的过继转移代表了一种有前途的免疫相关疾病治疗策略。在这篇综述中,我们总结了基于 MDSC 的细胞治疗在移植和自身免疫性疾病中的相关研究,并讨论了基于 MDSC 的细胞治疗临床应用的挑战和未来方向。

相似文献

1
Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.
Cell Immunol. 2021 Apr;362:104300. doi: 10.1016/j.cellimm.2021.104300. Epub 2021 Feb 4.
2
Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy.
J Transl Med. 2018 Jan 29;16(1):19. doi: 10.1186/s12967-018-1395-9.
3
Roles of Myeloid-Derived Suppressor Cell Subpopulations in Autoimmune Arthritis.
Front Immunol. 2018 Dec 4;9:2849. doi: 10.3389/fimmu.2018.02849. eCollection 2018.
4
Emerging Role of Myeloid-derived Suppressor Cells in the Biology of Transplantation Tolerance.
Transplantation. 2020 Mar;104(3):467-475. doi: 10.1097/TP.0000000000002996.
5
Myeloid suppressor cells in cancer and autoimmunity.
J Autoimmun. 2017 Dec;85:117-125. doi: 10.1016/j.jaut.2017.07.010. Epub 2017 Jul 17.
6
Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.
Inflammopharmacology. 2021 Oct;29(5):1307-1315. doi: 10.1007/s10787-021-00846-3. Epub 2021 Jul 20.
7
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. doi: 10.1038/s41392-021-00670-9.
8
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
Front Immunol. 2019 May 3;10:949. doi: 10.3389/fimmu.2019.00949. eCollection 2019.
9
Metabolic reprogramming of myeloid-derived suppressor cells in the context of organ transplantation.
Cytotherapy. 2023 Aug;25(8):789-797. doi: 10.1016/j.jcyt.2023.04.010. Epub 2023 May 18.

引用本文的文献

1
A donor PD-1CD8 T-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease.
Signal Transduct Target Ther. 2025 Apr 2;10(1):120. doi: 10.1038/s41392-025-02183-1.
2
Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs.
Science. 2024 Dec 6;386(6726):eadl4793. doi: 10.1126/science.adl4793.
6
Myeloid-derived suppressor cells in influenza virus-induced asthma exacerbation.
Front Immunol. 2024 Apr 17;15:1342497. doi: 10.3389/fimmu.2024.1342497. eCollection 2024.
7
Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology.
J Immunol. 2023 May 1;210(9):1183-1197. doi: 10.4049/jimmunol.2200914.
9
The Function and Therapeutic Implications of TNF Signaling in MDSCs.
Biomolecules. 2022 Nov 3;12(11):1627. doi: 10.3390/biom12111627.
10
A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles.
RSC Adv. 2022 Oct 3;12(43):28104-28112. doi: 10.1039/d2ra04326b. eCollection 2022 Sep 28.

本文引用的文献

1
Myeloid-derived suppressor cells improve corneal graft survival through suppressing angiogenesis and lymphangiogenesis.
Am J Transplant. 2021 Feb;21(2):552-566. doi: 10.1111/ajt.16291. Epub 2020 Oct 8.
2
Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
Front Immunol. 2020 May 22;11:989. doi: 10.3389/fimmu.2020.00989. eCollection 2020.
3
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006.
4
Myeloid-Derived Suppressor Cells in Kidney Transplant Recipients and the Effect of Maintenance Immunotherapy.
Front Immunol. 2020 Apr 30;11:643. doi: 10.3389/fimmu.2020.00643. eCollection 2020.
6
High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma.
Cancer Immunol Immunother. 2020 Apr;69(4):513-522. doi: 10.1007/s00262-019-02476-9. Epub 2020 Jan 17.
7
The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells?
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4149-4158. doi: 10.1080/21691401.2019.1687504.
8
Emerging Role of Myeloid-derived Suppressor Cells in the Biology of Transplantation Tolerance.
Transplantation. 2020 Mar;104(3):467-475. doi: 10.1097/TP.0000000000002996.
9
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.
Blood. 2019 Nov 7;134(19):1670-1682. doi: 10.1182/blood.2019001950.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验